Clinical Trial

Ex Vivo Expansion (ACT-X)

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand how the body's immune cells respond to a new type of vaccine (neoantigen vaccine) designed to help the immune system recognize and fight cancer. To do this, the study team will collect a research specimen from participants to study their immune cells' reactions to the neoantigen vaccine. This research will help researchers learn more about how these vaccines might work to protect or treat against cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-15; most recent amendment 2026-06-05.
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Trial Details
NCT Number NCT07137312
Lead Sponsor Mayo Clinic
Conditions Solid Tumor, Healthy, Malignant Solid Neoplasm
Enrollment 24 participants
Start Date 2025-12-16
Primary Completion 2028-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09